Hussman Strategic Advisors Inc. Takes $1.14 Million Position in Teladoc Health, Inc. $TDOC

Hussman Strategic Advisors Inc. bought a new position in shares of Teladoc Health, Inc. (NYSE:TDOC) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 147,000 shares of the health services provider’s stock, valued at approximately $1,136,000. Hussman Strategic Advisors Inc. owned 0.08% of Teladoc Health as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of TDOC. Mitsubishi UFJ Trust & Banking Corp lifted its position in Teladoc Health by 10.5% during the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 138,474 shares of the health services provider’s stock valued at $1,070,000 after buying an additional 13,159 shares in the last quarter. Bank Hapoalim BM raised its stake in shares of Teladoc Health by 48.8% in the 3rd quarter. Bank Hapoalim BM now owns 132,741 shares of the health services provider’s stock valued at $1,026,000 after acquiring an additional 43,541 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in shares of Teladoc Health during the 3rd quarter valued at $88,000. Concurrent Investment Advisors LLC purchased a new stake in Teladoc Health during the 3rd quarter worth $94,000. Finally, Bayforest Capital Ltd acquired a new stake in Teladoc Health in the 3rd quarter valued at $58,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Teladoc Health Price Performance

TDOC stock opened at $5.75 on Thursday. The stock’s 50 day moving average is $7.10 and its two-hundred day moving average is $7.62. Teladoc Health, Inc. has a 52-week low of $5.70 and a 52-week high of $15.21. The company has a market capitalization of $1.02 billion, a PE ratio of -4.49 and a beta of 2.04. The company has a quick ratio of 2.60, a current ratio of 2.70 and a debt-to-equity ratio of 0.71.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, October 29th. The health services provider reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.05. The company had revenue of $626.44 million during the quarter, compared to analysts’ expectations of $625.66 million. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.The business’s revenue was down 2.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.19) EPS. Analysts predict that Teladoc Health, Inc. will post -1.16 earnings per share for the current fiscal year.

Insider Activity at Teladoc Health

In other news, insider Carlos Nueno sold 3,897 shares of the company’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total value of $29,188.53. Following the sale, the insider owned 27,175 shares in the company, valued at approximately $203,540.75. This represents a 12.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Charles Divita III sold 17,138 shares of Teladoc Health stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the transaction, the chief executive officer owned 201,036 shares of the company’s stock, valued at $1,533,904.68. This trade represents a 7.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 33,288 shares of company stock valued at $251,684. 0.58% of the stock is owned by insiders.

Wall Street Analyst Weigh In

TDOC has been the topic of a number of recent research reports. Citigroup reduced their price objective on Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Friday, January 9th. Bank of America dropped their target price on Teladoc Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Tuesday, November 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a report on Monday, December 29th. Barclays started coverage on shares of Teladoc Health in a research report on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 price objective for the company. Finally, Zacks Research cut shares of Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Three analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Teladoc Health currently has a consensus rating of “Hold” and an average target price of $9.12.

Teladoc Health Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.